The mainstay therapy for locally advanced non-small cell lung cancer is concurrent chemoradiotherapy. Loco-regional recurrence constitutes the predominant failure patterns. Previous studies confirmed the relationship between increased biological equivalent doses and improved overall survival. https://www.roneverhart.com/DigiWeigh-Notebook-Digital-Pocket-Scale-1000g-x-0-1g/